PTC Therapeutics Inc (PTCT)

[legalizeMJ]

PTCT vs SMMT(DMD stocks comparisons)

1)PTCT and SMMT are DMD stocks.

2)On 9/26/16, SMMT Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular Dystrophy(DMD).
Here's the link:

https://finance.yahoo.com/news/summit-receives-fast-track-designation-110000521.html

3)PTCT= $11.66 per share
5)SMMT= $9.6 per share and its float is only 6ml shares.

6)SMMT has more upside potential because its pps is the smallest, only $9.6 per share AND SMMT Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular Dystrophy(DMD).

[Moto260]

Looks like a major short for next week

[CHIKILIN]

$11.47 +0.53 (4.84%) as of 11:31 AM

[chainma1l]

Yeah, keep posting that on the PTCT board where there has been one poster in months. I already have my allotment of SRPT--average under $11. I'll not be averaging up. I will be selling before I buy more.

[legalizeMJ]

Link:SRPT drug get approved, price target=$88.per share.

https://www.thestreet.com/story/13744847/1/sarepta-srpt-stock-upgraded-on-dmd-drug-approval.html?puc=TSMKTWATCH&cm_ven=TSMKTWATCH

Additionally, William Blair analysts noted that Sarepta should "move into a hyper-growth phase" of profit generation as there is currently no competition in the DMD drug market.

William Blair upgraded the stock to "outperform" from "market perform" and set its price target at $88.

Within 2 weeks from today, SRPT stock will be above $188.(one hundred eighty eight dollars)per shares on short squeezes because SRPT is a heavily shorted stock.
SRPT is a strong BUY.

[legalizeMJ]

Buy SRPT shares to profit from the first(the one and only) DMD drug approval.

SRPT has NO competition!!!

[ClayTrader]

* * $PTCT Video Chart 09-19-16 * *

Link to Video - click here to watch the technical chart video

[chainma1l]

SRPT was a strong buy last week when Farkas left. I was able to add 1,000 shares to my holdings and that worked out very well.
PTCT is the speculative play now. Already has approval in England and a renewal in Europe is pending. Company already has $60+ million in sales per year. They don't treat the same form of DMD that Sarepta does, so with Farkas gone, that is a VERY good sign. Hopefully the FDA comes through for PTC as well. If it does, the pps should see appreciation similar to SRPT.

[legalizeMJ]

SRPT shares leap 90% after FDA approves drug on 9/19/2016.

SRPT= Strong BUY.

[legalizeMJ]

SRPT:Approved / CNBC

http://www.cnbc.com/2016/09/19/sarepta-therapeutics-shares-briefly-leap-80-after-fda-approves-eteplirsen-drug.html

SRPT is a strong BUY.

[chainma1l]

Swingers have to be making a killing off PTCT.
It'd sure be nice to see the European approval finalized. Be nice to see the FDA do things a little more efficiently than they do.

http://www.thecoastnews.com/2016/08/28/family-anxiously-awaits-outcome-of-pharmaceutical-company-fda-battle

http://www.thefoundersdaily.com/ptc-therapeutics-ptct-receives-price-target/662811

[chainma1l]

Great earnings, great CC. Back to $50+ it goes.

[chainma1l]

Final UK approval:

http://www.pharmafile.com/news/505719/nice-recommends-ptc-therapeutics-duchenne-muscular-dystrophy-treatment

PTC Therapeutics has announced that the National Institute for Health and Care Excellence has issued final guidance recommending Translarna (ataluren) for ambulatory patients aged five and over with nonsense mutation Duchenne muscular dystrophy in connection with a managed access agreement with NHS England.

A rare genetic disease, primarily affecting males, Duchenne muscular dystrophy is a progressive muscular disorder caused by the lack of functional dystrophin protein. Disease sufferers lose the ability to walk from as early as 10 years old, and may begin to experience to potentially fatal lung and heart complications in their late teens and early twenties.

While rejected by the FDA in the US, Translarna has been approved by the EMA. NICE had backed the drug in initial guidance, and this latest guidance will mean Duchenne patients can now access the first approved therapy to treat the underlying causes of the disease.

Paul Lenihan, CEO of Action Duchenne, says: “We are delighted that this positive recommendation from NICE has now been published. This is such an important day for the Duchenne community, which has been working hard to make this ground-breaking drug available to boys with nonsense mutation Duchenne muscular dystrophy.”

Janis Clayon, General Manager for UK and Ireland at PTC Therapeutics, comments: “Translarna is the first and only licensed treatment to address the underlying cause of Duchenne muscular dystrophy. I am very pleased that the completion of this important review process undertaken by NICE and NHS England now ensures that a much-needed therapy is available for the children and young adults with nonsense mutation DMD that meet the requirements for the MAA.”

[chainma1l]

Would NHS have bothered with this MAA if NICE wasn't on board already?
EMA review could be announced at any time now. What happens if they say that the yearly review is no longer necessary? $20+?

8:19 am PTC Therapeutics negotiates a managed access agreement for Translama for ambulatory patients aged 5 years and older with nonsense mutation Duchenne muscular dystrophy (PTCT) :

Translarna is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation.
•This decision provides reimbursed patient access to Translarna in England via a five-year MAA.
•NICE is expected to issue final guidance later this month following execution of the MAA, with implementation soon after.
•PTC and NHS England have now finalized the outstanding aspects of the MAA which include a confidential financial arrangement and the collection of further data on the efficacy of Translarna for the treatment of nmDMD over a five-year period with NICE guidance to be reviewed again at the end of that period, before future funding decisions are taken.
•An opinion on renewal of Translama is expected mid-2016 by the EMA

[girlfriend]

Thank you…..I am also wondering if there would be any reaction in sympathy to the wait and see approval for Serapta's drug of which the FDA recently requested more information of.

[chainma1l]

Potential UK renewal review of Ataluren this week.
I would expect acquisition talk to start up again if UK reapproves it.
PTC will get FDA approval, just a question of when. Potential acquirers know this.

[girlfriend]

Hello any catalysts coming up soon for PTCT? Wanting to get back in here under 6.50 cash looks solid still large institutional ownership anything coming up to move this higher?

[traderinvestor]

PTCT should climb tomorrow and breakout imo based on SRPT update this evening. PTCT a much better bet imo with more upside potential.

[traderinvestor]

PTCT going HIGHER! Postive Data and news this month is due from UK. Expecting explosive move soon.

[chainma1l]

And Biomarin just stopped development on their current DMD drug, so that leaves a potential extra piece of the pie for somebody. Their drug (and Sarepta's) was not going to compete directly (at least initially) with PTC, so that wouldn't have bothered PTC. It'll be interesting to see what the UK says in their next review. I don't think they are going to be able to take Ataluren away from people and that is only going to help PTC's case with the FDA.

I'm not a fan of seekingalpha in general, but this article is probably worth a read:
http://seekingalpha.com/article/3956755-ptc-therapeutics-discounted-enterprise-value-despite-current-sales

The quote from the conference call also gives hope for Translarna in Germany and the rest of the continent as the GBA believes that this treatment has a quantifiable benefit:

“
And just to remind you, the GBA, which is the health technology assessment study in Germany already opined on the value of Translarna and gave the drug a rating of 3 on a scale of 1 to 6, where 1 is the highest and 6 is the lowest. About 50% of orphan drugs that go into the Germany HTA process get a 4 or a non-quantifiable benefit, whereas Translarna was given a 3 or a quantifiable benefit. So when it comes to patients requesting access to the drug, not only is it a drug that the insurers will see has been given a 3 from a medical value perspective, but it's the only approved drug for what is a very life-threatening condition.
"

[Ducimotto]

I think we are moving upwards a little because of Sarepta's news.

Sarepta Therapeutic's (NASDAQ: SRPT) 11% LOWER; Jefferies analyst, Gena Wang, hosted a call with FDA regulatory expert Dr. Brian Harvey on the PDUFA postponement for Sarepta Therapeutic's (NASDAQ: SRPT) eteplirsen. Involvements of senior FDA officials could be the reason for the delay and he says approval based on weak data could lead to significant consequences including perceived inconsistency and shift in future trial design. The analyst sees a slim chance of approval given a likely data driven decision by the FDA under current laws.

http://www.streetinsider.com/Special+Reports/Pre-Open+Stock+Movers+0602%3A+%28BWEN%29+%28RPRX%29+%28CIEN%29+Higher%3B+%28CONN%29+%28SRPT%29+%28DV%29+Lower+%28more...%29/11701124.html

[traderinvestor]

Nailed it again. GOING HIGHER! Trend is your friend. PTCT is bullish and ready to rock.

[traderinvestor]

Like I said it's going higher. Breakout looks imminent in a big way.

[traderinvestor]

$PTCT should gap and run tomm... expecting a breakout to continue with the recent data and super positive article out. This can easily run back to teens short term

[balamidas]

nice action on PTCT !

[traderinvestor]

Super bullish article out today on PTCT. The move up is here.

[balamidas]

looks good

[traderinvestor]

Monster Short squeeze potential right now with NICE update due. Fasten your seat belt. Expecting rocket gains here near term.

[traderinvestor]

Bulls in charge. Short squeeze beginning imo. Major news do with NICE this month.

[Jenkens]

No treatment for DMD exists-- BioMarin, Sarepta’s Loss Could Be PTC Therapeutic’s Gain

http://marketexclusive.com/biomarin-sareptas-loss-could-be-ptcs-gain/1419/

[balamidas]

nice action ah !

[traderinvestor]

Major Bullish News out!

[balamidas]

looks that way !

[traderinvestor]

BULLISH REVERSAL CONFIRMED!

[traderinvestor]

Bulls back in charge! Shorts getting squeezed next week!

[traderinvestor]

New short term high coming this week imo.

[balamidas]

good point !

[traderinvestor]

PTCT easy money between now and May with the APPROVAL. Looking for a quick and big return here.

[traderinvestor]

It was a buy. If it was the latter it would of been done after hours sometime once calculating the inbalance from the day and then thrown on the tape.

[Wifesmoney]

Not a buy, just bringing books back to order

[OTC_evolutionX]

47962 BUY @4PM.. NICE $PTCT

[pberger]

See? Barely at $8 now.

[pberger]

Why? Pre-market is bad.
Most probably will continue to cool down on no news.
I'm selling at open to buy back, maybe, in a few weeks below $7.

[balamidas]

http://finance.yahoo.com/news/nice-recommends-translarna-ataluren-treatment-151600792.html

[dieanotherday]

Not sure why the class action lawsuit would cause this stock to go up? Am I missing something?

[ClayTrader]

* * $PTCT Video Chart 04-15-16 * *

Link to Video - click here to watch the technical chart video

[Flagship]

Agree 12-15 very soon!

[OB_WEALTH_INC]

MONDAY BREAKOUT WATCH AT $10

[INTL]

Love plays like this. Building a head of steam on great news. Small float + Friday afternoon short squeeze. Great way to end a great week!

[UP Trend]

Shorties feeling the burn..lol